ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 572,12
-0,79%
Dow Jones
40 211,72
0,00%
DAX
18 492,45
-0,58%
Brent Oil
83,025
-1,56%
Bitcoin
64 030,28
-1,25%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Allos Therapeutics, Inc. (MM) (ALTH)

  7. Allos Therapeutics, Inc. (MM) (ALTH) Actualités

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALTH
DateHeureSourceTitreSymboleSociété
29/07/200415h00PR Newswire (US)Allos Therapeutics to Hold Q2 2004 Financial Results Conference Call and Webcast on Tuesday, August 3NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
16/06/200415h01PR Newswire (US)Allos Therapeutics Announces New Trade Names for Efaproxiral in the U.S. and EuropeNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/06/200415h00PR Newswire (US)Allos to Present at Needham and Company's Third Annual Biotechnology ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/06/200415h01PR Newswire (US)Data Presented at ASCO Demonstrate That Red Blood Cell Levels of Allos Therapeutics' RSR13 Correlate With Treatment Effect in PaNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
06/06/200420h05PR Newswire (US)Data From Phase 3 Trial of Allos Therapeutics' RSR13 (efaproxiral) Presented at ASCONASDAQ:ALTH
06/06/200419h23PR Newswire (US)Analysis From Phase 3 Trial Suggests That Some Non-Small Cell Lung Cancer Patients With Brain Metastases May Benefit From AllosNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/06/200415h00PR Newswire (US)Allos Therapeutics Files Application for European Marketing Approval of RSR13 (efaproxiral)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
02/06/200416h00PR Newswire (US)Federman & Sherwood Announces That a Securities Class Action Lawsuit Was Filed Against Allos Therapeutics, Inc.NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
02/06/200415h00PR Newswire (US)Allos Therapeutics Receives FDA Approvable Letter for RSR13 (efaproxiral)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
28/05/200415h00PR Newswire (US)Abstracts on Allos Therapeutics' RSR13 to Be Presented at American Society of Clinical Oncology Annual MeetingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
25/05/200418h23PR Newswire (US)Wolf Haldenstein Adler Freeman and Herz LLP Commences Class Action Lawsuit on Behalf of Allos Therapeutics, Inc. ShareholdersNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
24/05/200423h13PR Newswire (US)Geller Rudman Announces Class Action Lawsuit Against Allos Therapeutics, Inc. on Behalf of InvestorsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
24/05/200422h13PR Newswire (US)Shareholder Class Action Filed Against Allos Therapeutics, Inc. by the Law Firm of Schiffrin & Barroway, LLPNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
22/05/200400h00PR Newswire (US)Weinstein Kitchenoff Scarlato Karon & Goldman Ltd. Announces Class Action Lawsuit Against Allos Therapeutics, Inc.NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
06/05/200413h00PR Newswire (US)Allos Therapeutics Reports First Quarter 2004 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/05/200400h25PR Newswire (US)Allos Therapeutics to Hold Q1 2004 Financial Results Conference Call and Webcast on Thursday, May 6NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/05/200400h04PR Newswire (US)FDA Advisory Committee Does Not Recommend Approval of RSR13 as Adjunctive Therapy for the Treatment of Brain Metastases OriginatNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/04/200423h30PR Newswire (US)Allos to Discuss ODAC Panel Recommendation on Monday May 3, 2004NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
12/03/200420h54PR Newswire (US)Allos NDA to be Reviewed by FDA Advisory CommitteeNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/03/200421h17PR Newswire (US)American Stock Exchange to Trade Options on Three SecuritiesNASDAQ:ALTH
06/03/200400h59PR Newswire (US)Allos Therapeutics Files Shelf Registration StatementNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
12/02/200413h45PR Newswire (US)Reminder - Allos Therapeutics Management Conference CallNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
12/02/200413h00PR Newswire (US)Allos Begins Phase 3 Study of RSR13 in Women With Brain Metastases From Breast CancerNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
12/02/200412h00PR Newswire (US)Allos Therapeutics Reports Fourth Quarter and Year-End 2003 ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/12/200312h00PR Newswire (US)Allos Completes New Drug Application for Novel Treatment for Patients With Breast Cancer and Brain MetastasesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/12/200323h30PR Newswire (US)Arizona Cancer Center Investigator Presents Positive Survival and Quality of Life Data From RSR13 Phase 3 StudyNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
24/11/200313h00PR Newswire (US)Allos Therapeutics Announces RSR13 Phase 3 Results in Patients With Breast Cancer and Brain Metastases Will Be Highlighted at thNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/11/200323h24PR Newswire (US)Allos Therapeutics Completes $12 Million Private PlacementNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
18/11/200318h30PR Newswire (US)Allos Therapeutics Announces Presentation of Phase 1 Results of PDX in Patients With Advanced Non-Small Cell Lung CancerNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/11/200312h00PR Newswire (US)Allos Therapeutics Announces Presentation of RSR13 Phase 3 Results in Brain Metastases at the Eighth Annual Meeting of the SocieNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Showing the most relevant articles for your search:NASDAQ:ALTH

Dernières Valeurs Consultées

EU
VIV
Vivendi
EU
HO
Thales
NYSE
MCD
McDonalds
EU
ACA
Credit Agricole
EU
RI
Pernod Ricard
NYSE
NKE
Nike
EU
BNP
BNP Paribas
EU
PX4
SBF 120
EU
CAP
Capgemini
NASDAQ
NVDA
NVIDIA
EU
RNO
Renault
NYSE
KO
Coca Cola
EU
BEL20
Bel 20
EU
BN
Danone
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés